2.15
price down icon4.44%   -0.10
after-market アフターアワーズ: 2.20 0.05 +2.33%
loading
前日終値:
$2.25
開ける:
$2.28
24時間の取引高:
5.57M
Relative Volume:
2.41
時価総額:
$250.60M
収益:
$6.65M
当期純損益:
$-136.32M
株価収益率:
-1.8733
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
+13.76%
1か月 パフォーマンス:
+61.65%
6か月 パフォーマンス:
+95.45%
1年 パフォーマンス:
+85.34%
1日の値動き範囲:
Value
$2.09
$2.31
1週間の範囲:
Value
$1.785
$2.315
52週間の値動き範囲:
Value
$0.91
$2.465

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1111)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
161
Name
Twitter
@fatethx
Name
次回の収益日
2026-05-12
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FATE icon
FATE
Fate Therapeutics Inc
2.15 262.26M 6.65M -136.32M -112.04M -1.1477
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.93 110.28B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
634.62 66.98B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
808.43 50.15B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
295.50 39.71B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
154.89 32.22B 742.00K -1.37B -1.07B -7.0731

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-31 アップグレード H.C. Wainwright Neutral → Buy
2025-10-27 アップグレード Wedbush Neutral → Outperform
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
May 22, 2026

BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo

May 22, 2026
pulisher
May 22, 2026

FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

May 22, 2026
pulisher
May 21, 2026

Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK

May 21, 2026
pulisher
May 21, 2026

Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com Australia

May 21, 2026
pulisher
May 21, 2026

Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider

May 21, 2026
pulisher
May 21, 2026

Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com

May 21, 2026
pulisher
May 21, 2026

Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR - Stock Titan

May 21, 2026
pulisher
May 20, 2026

Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com India

May 20, 2026
pulisher
May 20, 2026

[144] FATE THERAPEUTICS INC SEC Filing - Stock Titan

May 20, 2026
pulisher
May 20, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - TradingView

May 20, 2026
pulisher
May 19, 2026

Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential By Investing.com - Investing.com South Africa

May 19, 2026
pulisher
May 19, 2026

Jefferies Initiates Fate Therapeutics(FATE.US) With Buy Rating, Announces Target Price $4 - Moomoo

May 19, 2026
pulisher
May 14, 2026

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill

May 14, 2026
pulisher
May 13, 2026

Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $2.25 - Moomoo

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Key Disclosures - Minichart

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada

May 13, 2026
pulisher
May 13, 2026

FT819 Remodels Lupus B Cells in Clinical Trial - CRISPR Medicine News

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics Reports Q1 2026 Financial Results, Advances FT819 and FT839 CAR T-Cell Trials with Extended Cash Runway into 2028 - Minichart

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics (NASDAQ: FATE) narrows Q1 2026 loss as R&D costs fall - Stock Titan

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary - TradingView

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028 - TradingView

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics: Q1 Earnings Snapshot - KTVB

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics reports Q1 2026 net loss $31.2M, cash and investments $174.8M; runway into 2028 - TradingView

May 13, 2026
pulisher
May 13, 2026

Fate Therapeutics (NASDAQ: FATE) trims Q1 loss, extends cash runway and advances FT819 - Stock Titan

May 13, 2026
pulisher
May 12, 2026

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 (NASDAQ:FATE) - Seeking Alpha

May 12, 2026
pulisher
May 12, 2026

FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan

May 12, 2026
pulisher
May 12, 2026

Fate Therapeutics presents CAR T-cell therapy data at ASGCT - Investing.com UK

May 12, 2026
pulisher
May 11, 2026

Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com - Investing.com South Africa

May 11, 2026
pulisher
May 11, 2026

Fate Therapeutics Showcases FT819 Clinical Activity in SLE - GlobeNewswire

May 11, 2026
pulisher
May 09, 2026

Fate Therapeutics (FATE) Eps Diluted (TTM) - Zacks Investment Research

May 09, 2026
pulisher
May 09, 2026

Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

May 09, 2026
pulisher
May 09, 2026

MSN Money - MSN

May 09, 2026
pulisher
May 08, 2026

FATE Technical Analysis | Trend, Signals & Chart Patterns | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

May 08, 2026
pulisher
May 07, 2026

Fate Therapeutics Inc (FATE) Stock Price Today & Analysis - Gotrade

May 07, 2026
pulisher
May 07, 2026

Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates - Stocktwits

May 07, 2026
pulisher
May 06, 2026

Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options - Stock Titan

May 06, 2026
pulisher
May 06, 2026

FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake - Stock Titan

May 06, 2026
pulisher
May 06, 2026

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo

May 06, 2026
pulisher
May 06, 2026

HC Wainwright Issues Positive Estimate for FATE Earnings - MarketBeat

May 06, 2026
pulisher
May 06, 2026

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo

May 06, 2026
pulisher
May 05, 2026

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com India

May 05, 2026
pulisher
May 05, 2026

Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

May 05, 2026
pulisher
May 05, 2026

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com

May 05, 2026
pulisher
May 05, 2026

Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - The Manila Times

May 05, 2026

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
大文字化:     |  ボリューム (24 時間):